Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty
Open Access
- 1 November 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 3 (6) , 652-660
Abstract
Background—: Dabigatran and rivaroxaban are novel oral anticoagulants approved for prevention of venous thromboembolism after hip or knee arthroplasty. However, information assessing clinically important efficacy and bleeding outcomes of these 2 new agents versus low-molecular-weight heparin (enoxaparin) is lacking. Methods and Results—: We separately pooled efficacy and safety data from 6 phase III randomized trials (18 405 participants) comparing equivalent durations of treatment with enoxaparin (40 mg once daily [od] or 30 mg twice daily) versus dabigatran (220 mg od) or versus rivaroxaban (10 mg od) after hip or knee arthroplasty. Odds ratios (OR) for individual outcomes were calculated for each trial and were pooled using the Mantel-Haenszel method. Compared with dabigatran, enoxaparin had a similar risk of symptomatic venous thromboembolism plus all-cause mortality (0.9% versus 1.1%; OR, 0.76; 95% confidence interval [CI], 0.44 to 1.31; I 2 =76%) and bleeding (5.0% versus 5.6%; OR, 0.90; 95% CI, 0.71 to 1.15; I 2 =0%). Compared with rivaroxaban, enoxaparin had a 2-fold higher risk of symptomatic venous thromboembolism plus all-cause mortality (1.2% versus 0.6%; OR, 2.04; 95% CI, 1.32 to 3.17; P 2 =0%) but demonstrated a significant lower risk of bleeding (2.5% versus 3.1%; OR, 0.79; 95% CI, 0.62 to 0.99; P =0.049; number needed to harm, 167; I 2 =0%). Conclusions—: In patients undergoing hip or knee arthroplasty, enoxaparin and dabigatran showed similar rates of efficacy and bleeding. Enoxaparin was less effective than rivaroxaban but had a lower risk of bleeding. These results may have important implications for the choice of prophylactic agent in major joint arthroplasty.Keywords
This publication has 20 references indexed in Scilit:
- Duration and magnitude of the postoperative risk of venous thromboembolism in middle aged women: prospective cohort studyBMJ, 2009
- Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trialThe Lancet, 2009
- Oral Thrombin Inhibitor Dabigatran Etexilate vs North American Enoxaparin Regimen for Prevention of Venous Thromboembolism After Knee Arthroplasty SurgeryThe Journal of Arthroplasty, 2009
- Mandated Venous Thromboembolism ProphylaxisThe Journal of Arthroplasty, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip ArthroplastyNew England Journal of Medicine, 2008
- Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee ArthroplastyNew England Journal of Medicine, 2008
- Prevention of Venous ThromboembolismChest, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trialThe Lancet, 2007
- Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic eventsThe Journal of Bone and Joint Surgery. British volume, 2007